Tech Company Financing Transactions
Affini-T Therapeutics Funding Round
Affini-T Therapeutics, based in St. Watertown, secured $175 million in investment from ARM, Agent Capital and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
3/22/2022
Transaction Type
Venture Equity
Amount
$175,000,000
Round
Undisclosed
Investors
Proceeds Purpose
for cell therapies to treat solid tumors
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
343 Arsenal
St. Watertown, MA 02472
USA
St. Watertown, MA 02472
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Developer of therapeutics platform intended to target oncogenic driver mutations. The company specializes in providing immune cell technology which unlocks the power of T cells that leverages synthetic biology and gene editing technologies to outsmart the immunosuppressive tumor microenvironment and generate a sustained anti-tumoral response, enabling doctors to deliver transformative therapies intended to cure patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jak Knowles
Chief Operating Officer
Kathy Yi
Chief Scientific Officer
Loïc Vincent
Chief Technical Officer
Kim Nguye
Browse more venture capital transactions:
Prev: 3/22/2022: Muni Tienda venture capital transaction
Next: 3/22/2022: Piñata Global venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs